Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart

被引:266
|
作者
Heymans, S
Schroen, B
Vermeersch, P
Milting, H
Gao, FY
Kassner, A
Gillijns, H
Herijgers, P
Flameng, W
Carmeliet, P
de Werf, FV
Pinto, YM
Janssens, S
机构
[1] Univ Maastricht, Expt & Mol Cardiol CARIM, Maastricht, Netherlands
[2] Katholieke Univ Leuven, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium
[3] Katholieke Univ Leuven Hosp, Dept Cardiovasc Surg, B-3000 Louvain, Belgium
[4] Katholieke Univ Leuven Hosp, Dept Cardiol, B-3000 Louvain, Belgium
[5] Ruhr Univ Bochum, Univ Klin, Herz & Diabeteszentrum NRW, Erich & Hanna Klessmann Inst Kardiovaskulare Fors, Bad Oeynhausen, Germany
关键词
metalloproteinases; remodeling; hypertrophy; hypertension; collagen;
D O I
10.1161/CIRCULATIONAHA.104.516963
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background - Alterations in the balance of matrix metalloproteinases ( MMPs) and their specific tissue inhibitors (TIMPs) are involved in left ventricular (LV) remodeling. Whether their expression is related to interstitial fibrosis or LV dysfunction in patients with chronic pressure overload - induced LV hypertrophy, however, is unknown. Methods and Results - Therefore, cardiac biopsies were taken in 36 patients with isolated aortic stenosis ( AS) and in 29 control patients without LV hypertrophy. Microarray analysis revealed significantly increased mRNA expression of collagen types I, III, and IV and transcripts involved in collagen synthesis, including procollagen endopeptidase and lysine and proline hydroxylases, in AS compared with control patients. Collagen deposition was greater in AS than in control patients and was most pronounced in AS patients with severe diastolic dysfunction. Cardiac mRNA expression of TIMP-1 and TIMP-2 was significantly increased in AS compared with control patients ( mRNA transcript levels normalized to GAPDH: TIMP-1, 0.67 +/- 0.1 in AS versus 0.37 +/- 0.08 in control patients; TIMP-2, 9.5 +/- 2.6 in AS versus 1.6 +/- 0.4 in control patients; P < 0.05 for both) but did not differ significantly for MMP-1, -2, or -9. Cardiac TIMP-1 and - 2 transcripts were significantly related to the degree of interstitial fibrosis and proportional to diastolic dysfunction in AS patients. Conclusions - Cardiac expression of TIMP-1 and TIMP-2 is significantly increased in chronic pressure-overloaded human hearts compared with controls and is related to the degree of interstitial fibrosis.
引用
收藏
页码:1136 / 1144
页数:9
相关论文
共 50 条
  • [21] Localization and expression of tissue inhibitor of metalloproteinase-1 in human urothelial cancer
    Yano, A
    Nakamoto, T
    Hashimoto, K
    Usui, T
    JOURNAL OF UROLOGY, 2002, 167 (02): : 729 - 734
  • [22] Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C - Relationship to interferon response
    Kasahara, A
    Hayashi, N
    Mochizuki, K
    Oshita, M
    Katayama, K
    Kato, M
    Masuzawa, M
    Yoshihara, H
    Naito, M
    Miyamoto, T
    Inoue, A
    Asai, A
    Hijioka, T
    Fusamoto, H
    Kamada, T
    JOURNAL OF HEPATOLOGY, 1997, 26 (03) : 574 - 583
  • [23] Expression of tissue inhibitor of matrix metalloproteinase-1 in human breast carcinoma
    Inoue, H
    Mimori, K
    Shiraishi, T
    Kataoka, A
    Sadanaga, N
    Ueo, H
    Barnard, GF
    Mori, M
    ONCOLOGY REPORTS, 2000, 7 (04) : 871 - 874
  • [24] Expression of Type IV Collagen, Metalloproteinase-2, Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 in Laryngeal Squamous Cell Carcinomas
    Cao, Xiao-Lin
    Xu, Ru-Jun
    Zheng, You-Yang
    Liu, Jun
    Teng, Yao-Shu
    Li, Yong
    Zhu, Jin
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (12) : 3245 - 3249
  • [25] Matrix metalloproteinase-2,-9 and tissue inhibitor metalloproteinase-1,-2 in healthy and type 2 diabetic subjects
    Derosa, Giuseppe
    D'Angelo, Angela
    Tinelli, Carmine
    Salvadeo, Sibillaa. T.
    Ciccarelli, Leonardina
    Piccinni, Mario N.
    Pricolo, Fabio
    Montagna, Lorenza
    Ghelfi, Morena
    Ferrari, Ilaria
    Gravina, Alessia
    Cicero, Arrigo F. G.
    DIABETES, 2006, 55 : A154 - A154
  • [26] Polymorphisms in the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 and the risk of human adenomyosis
    Kang, Shan
    Zhao, Xiwa
    Xing, Huimin
    Wang, Na
    Zhou, Rongmiao
    Chen, Shucheng
    Li, Wansheng
    Zhao, Jian
    Duan, Yanan
    Sun, Donglan
    Li, Yan
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2008, 49 (03) : 226 - 231
  • [27] FOLDING AND STABILITY OF THE ACTIVE N-TERMINAL DOMAIN OF TISSUE INHIBITOR OF METALLOPROTEINASE-1 AND METALLOPROTEINASE-2
    WILLIAMSON, RA
    BARTELS, H
    MURPHY, G
    FREEDMAN, RB
    PROTEIN ENGINEERING, 1994, 7 (08): : 1035 - 1040
  • [28] Differential expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 by human vascular smooth muscle cells
    Kato, S
    Yasukawa, H
    Fujii, T
    Miyagi, M
    Nishi, M
    Morimatsu, M
    Miyamoto, T
    Fox, JC
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 251 - 251
  • [29] Secretion of matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-1 and human chorionic gonadotropin by cytotrophoblastic cells: Is there a regulation by relaxin?
    Mock, P
    Meisser, A
    Araman, M
    Wuillemin, C
    Campana, A
    Bischof, P
    RELAXIN 2000, 2001, : 121 - 125
  • [30] Tissue Inhibitor of Metalloproteinase-2 Gene Delivery Ameliorates Postinfarction Cardiac Remodeling
    Ramani, Ravi
    Nilles, Kathleen
    Gibson, Gregory
    Burkhead, Benjamin
    Mathier, Michael
    McNamara, Dennis
    McTiernan, Charles F.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2011, 4 (01): : 24 - 31